SRSA
ABBV icon

S.R. Schill & Associates’s AbbVie ABBV Stock Holding History

S.R. Schill & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,345
Closed -$574K – 40
2024
Q2 		$574K Sell
3,345
-2,718
-45% -$450K 0.25% 40
2024
Q1 		$1.1M Sell
6,063
-305
-5% -$52.6K 0.48% 28
2023
Q4 		$987K Sell
6,368
-3
-0% -$437 0.44% 28
2023
Q3 		$950K Hold
6,371
– – 0.46% 25
2023
Q2 		$858K Hold
6,371
– – 0.39% 26
2023
Q1 		$1.02M Hold
6,371
– – 0.47% 24
2022
Q4 		$1.03M Sell
6,371
-148
-2% -$22.7K 0.51% 25
2022
Q3 		$875K Buy
6,519
+1,355
+26% +$194K 0.47% 25
2022
Q2 		$791K Hold
5,164
– – 0.4% 26
2022
Q1 		$837K Sell
5,164
-2,129
-29% -$309K 0.35% 28
2021
Q4 		$987K Sell
7,293
-978
-12% -$116K 0.39% 27
2021
Q3 		$892K Buy
8,271
+215
+3% +$24.6K 0.38% 31
2021
Q2 		$907K Hold
8,056
– – 0.36% 34
2021
Q1 		$872K Buy
8,056
+250
+3% +$26.7K 0.38% 36
2020
Q4 		$836K Sell
7,806
-675
-8% -$64.9K 0.39% 31
2020
Q3 		$743K Buy
8,481
+1,919
+29% +$181K 0.38% 32
2020
Q2 		$644K Buy
6,562
+2,828
+76% +$249K 0.38% 36
2020
Q1 		$284K Sell
3,734
-17
-0.5% -$1.45K 0.19% 55
2019
Q4 		$332K Buy
3,751
+490
+15% +$40.7K 0.18% 68
2019
Q3 		$247K Buy
3,261
+347
+12% +$23.8K 0.14% 69
2019
Q2 		$212K Hold
2,914
– – 0.13% 73
2019
Q1 		$235K Hold
2,914
– – 0.14% 72
2018
Q4 		$269K Hold
2,914
– – 0.19% 68
2018
Q3 		$276K Buy
2,914
+750
+35% +$71.1K 0.17% 73
2018
Q2 		$200K Buy
+2,164
New +$211K 0.12% 78

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

S.R. Schill & Associates's ABBV Position: Q3 2024 in Review

S.R. Schill & Associates sold out of AbbVie (ABBV) in Q3 2024, closing a stake of 3,345 shares — an estimated $574K sold.

S.R. Schill & Associates first reported a position in ABBV in Q2 2018 and held it in 25 quarters. The position peaked at $1.1M in Q1 2024. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

  • S.R. Schill & Associates reported no remaining AbbVie position as of Q3 2024 after selling out during the quarter.
  • S.R. Schill & Associates sold 3,345 AbbVie shares in Q3 2024, an estimated $574K.
  • S.R. Schill & Associates first reported a position in AbbVie in Q2 2018 and held it in 25 quarters.
  • S.R. Schill & Associates's AbbVie position peaked at $1.1M in Q1 2024.
  • 3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on S.R. Schill & Associates's 13F filing for Q3 2024, filed 13 Nov 2024.